Pfizer Stock Price Forecast: Is $27 the Bottom? Oncology Wins and a $35 Price Target Make the Value Case Undeniable

Pfizer (PFE) is trading at $27.27 Friday, down 1.11% on the session, sitting just $0.67 below its 52-week high of $27.94 and roughly 30% above its 52-week low of $20.92. The market cap sits at $155.35 billion against a business generating $62.6 billion in annual revenue. The forward P/E non-GAAP is 8.35-9.31x — 45.3% below the healthcare sector median — while direct competitors Merck (MRK) trades at 23.3x forward earnings and Johnson & Johnson (JNJ) at 20.8x. That valuation gap is not subtle. At 8.35x, PFE is being priced as a business in structural decline. The actual evidence — a $4.44 billion oncology revenue quarter growing 9.1% year-over-year, BRAFTOVI securing the first-ever approval for BRAF V600E metastatic colorectal cancer, atirmociclib delivering a 40% reduction in disease progression risk in second-line breast cancer, Lorbrena sales up 46.9% year-over-year to $282 million — tells a materially different story. The market is wrong about Pfizer, and the valuation discount is the opportunity.

Q4 2025 Beat Was Real — But COVID Revenue Drag Is Masking the Underlying Strength

PFE reported Q4 2025 revenue of $17.56 billion, up 5.5% quarter-over-quarter and beating Wall Street consensus by $729 million. Non-GAAP EPS beat consensus by $0.09 — the eleventh consecutive quarterly beat. The stock jumped 7% on the day, outperforming the S&P 500 which fell 5.7% during the same period. Full-year 2025 revenue came in at $62.6 billion, with free cash flow of $9.08 billion — down from $9.84 billion in 2024 but still generating substantial cash. The negative headline is COVID-19 product revenue, which fell 39.4% year-over-year to $2.49 billion in Q4. Comirnaty and Paxlovid are structurally declining assets and CEO Albert Bourla has been transparent about that trajectory for 18 months. The critical analytical point is what the revenue picture looks like excluding COVID products — and that picture shows an oncology and cardiometabolic portfolio that is growing, winning clinical battles, and generating increasing commercial momentum. For 2026, PFE guides revenue of $59.5-$62.5 billion with adjusted diluted EPS of $2.80-$3.00, compared to $3.22 in 2025. That guidance already incorporates the negative effects of Most-Favored-Nation drug pricing and TrumpRx discounts — meaning the actual operational performance is expected to hold up better than the headline EPS trajectory suggests.

BRAFTOVI Approval: The Only Approved Drug for a $2B+ Market Opportunity

The most underappreciated near-term commercial development at PFE is BRAFTOVI receiving full FDA approval for first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer in late February 2026. BRAFTOVI is currently the only approved drug for this specific indication — a monopoly position in a defined patient population. The BRAF V600E mutation occurs in approximately 10% of metastatic colorectal cancer patients. The clinical data supporting the approval is extraordinary: the BRAFTOVI regimen delivered a 51% reduction in the risk of death and doubled median overall survival to 30.3 months from approximately 15 months with prior standard of care. A 51% mortality risk reduction in a cancer indication that had no targeted first-line approved option is the definition of clinical best-in-class performance. As it becomes the standard of care for BRAF V600E metastatic CRC — which it will, because there is no competitor — pricing will be substantial. This is a multi-hundred-million-dollar revenue ramp beginning in 2026 that the market has not yet priced into PFE's forward estimates.

Atirmociclib: Ibrance's Successor Is Already Winning Where It Counts

PFE's Ibrance generated $1.04 billion in Q4 revenue but fell 5% year-over-year as competition from Eli Lilly's Verzenio and Novartis' Kisqali intensified. Ibrance loses U.S. exclusivity in 2027 — a patent cliff event that has been cited repeatedly as a bear thesis anchor. The successor is already in Phase 3. Atirmociclib is a next-generation CDK4 inhibitor — specifically, it is a selective CDK4 inhibitor that does not block CDK6, unlike Ibrance, Verzenio, and Kisqali. The clinical significance of that selectivity is measurable: CDK6 inhibition causes neutropenia by suppressing neutrophil cell counts, weakening the immune system and increasing serious infection risk. Atirmociclib's CDK4-selective mechanism is expected to deliver a cleaner safety profile and potentially superior tolerability at equivalent or better efficacy. The Phase 2 FOURLIGHT-1 trial confirmed a 40% reduction in the risk of disease progression or death in second-line metastatic breast cancer patients who had previously progressed on CDK4/6 inhibitors — a population where switching to another CDK4/6 inhibitor typically provides minimal benefit. The statistical significance was P=0.0007. The efficacy held regardless of prior CDK4/6 inhibitor treatment duration or menopausal status. A pivotal Phase 3 trial in the first-line setting is actively enrolling. If atirmociclib wins that Phase 3, PFE does not just replace Ibrance — it reclaims breast cancer backbone leadership from Verzenio, which currently generates $3.6 billion annually for Eli Lilly.

Lorbrena Is Becoming a Blockbuster — 5-Year PFS of 60% vs. 8% Is Not a Close Race

Lorbrena (lorlatinib) is the most underappreciated commercial success in PFE's portfolio right now. Q4 sales hit $282 million, up 46.9% year-over-year, beating prior analyst estimates by $15 million. The clinical data underpinning that growth trajectory is remarkable. The five-year follow-up from the Phase 3 CROWN trial showed progression-free survival of 60% for lorlatinib patients versus 8% for the crizotinib control group at five years. That is not a marginal improvement — it is a seven-and-a-half-fold difference in the probability of being progression-free at five years. The intracranial progression-free rate at five years was 92% in the Lorbrena group versus 21% in crizotinib patients — a 71-percentage-point separation in preventing brain metastases, which are the primary driver of mortality and morbidity in ALK-positive NSCLC. As oncologists continue to digest five-year data showing this magnitude of separation, prescribing patterns will continue shifting toward lorlatinib as the definitive first-line standard for ALK-positive NSCLC. At $282 million in Q4 and growing at 47% year-over-year, Lorbrena is on track to become a $1 billion-plus annual revenue asset within 18 months. The market is not pricing that trajectory.

Talzenna + Xtandi: Prostate Cancer Approval Could Add $500M+ Revenue

On March 19, 2026, PFE announced that Talzenna in combination with Xtandi met the primary endpoint in the TALAPRO-3 trial for the treatment of certain patients with prostate cancer. Talzenna Q4 sales reached $49 million, up 81.5% year-over-year. That growth rate on a drug that has now won both prostate cancer and breast cancer trial data positions it as a multi-indication oncology asset with a significantly larger addressable market than its current revenue reflects. Prostate cancer is the most common cancer in men, with approximately 250,000 new cases annually in the United States. The PARP inhibitor combination approach in prostate cancer — which Talzenna represents — has become a standard-of-care evolution that AstraZeneca's olaparib pioneered and Pfizer is now competing in directly. HYMPAVZI additionally received FDA priority review status for pediatric and adult hemophilia A and B — another specialty indication with premium pricing potential and a defined patient population. The HEMB and HEMA market combined generates approximately $10 billion annually globally, and priority review status signals FDA acknowledgment of unmet need.

The Obesity Pipeline: PF-08653944 Is a Once-Monthly Injection That Could Rival Tirzepatide

PFE entered the GLP-1 obesity market through the Metsera acquisition in November 2025 and a separate up-to-$495 million deal with Sciwind in February 2026. The lead candidate is PF-08653944 — internally designated PF'3944 — a once-monthly maintenance injection that showed placebo-adjusted weight loss of 12.3% at 28 weeks with no plateau visible in the data curve. No plateau at 28 weeks is the critical observation: it means the efficacy ceiling has not yet been reached, implying that the final weight loss at the treatment endpoint will exceed 12.3%. Pfizer's own mathematical model projects 15.8% placebo-adjusted weight loss at week 28 for the high-dose 9.6mg monthly cohort — a figure that approaches the 20-22% benchmark set by Eli Lilly's tirzepatide. An indirect comparison showed PF'3944 superiority over Novo Nordisk's semaglutide. The obesity drug market is projected to exceed $100 billion by 2030. PFE is launching approximately 10 pivotal Phase 3 trials for PF'3944 in 2026, including the high-dose 9.6mg monthly cohort. Monthly dosing versus weekly injections for Ozempic/Wegovy is a meaningful patient convenience advantage that can drive formulary preference and commercial differentiation. If PF'3944 delivers 15-18% weight loss in Phase 3, PFE enters a $100 billion market with a differentiated dosing profile at a time when the market cap implies the obesity upside is worth zero.

The Patent Cliff Is Real — But the Market Is Overpricing the Risk

The bear case on PFE centers on the loss-of-exclusivity cycle: Eliquis, Ibrance, Vyndaqel, and Prevnar 13 collectively face projected annual revenue loss of $17-$18 billion by the end of the decade. These are not hypothetical risks — Ibrance loses U.S. exclusivity in 2027, Xtandi exclusivity ends at the same time. The combined revenue at risk is substantial. However, several factors mitigate the severity of the cliff. First, drugs rarely lose 100% of revenue immediately upon patent expiration — generic penetration is gradual, and branded versions often retain 20-40% of prior revenue for years post-LOE. Second, Eliquis is a co-promotion with Bristol-Myers Squibb, meaning only a portion of the LOE impact falls on PFE. Third, the oncology portfolio is now generating $4.44 billion per quarter growing at 9.1% year-over-year — a run rate that offsets a significant portion of the projected LOE revenue erosion. Fourth, BRAFTOVI, atirmociclib, Lorbrena, Talzenna, and the obesity pipeline represent new revenue streams that are beginning to materialize precisely as the LOE cycle commences. CEO Bourla characterized 2026 as the "inflection point" — the first year of the LOE cycle but also the year where the replacement pipeline begins generating commercial scale. The market is pricing the LOE risk without simultaneously pricing the replacement pipeline upside. That asymmetry is the fundamental investment thesis.

TrumpRx and Most-Favored-Nation Pricing: Risk Managed, Not Eliminated

TrumpRx launched officially with PFE offering more than 30 brands at an average discount of 50%, with some treatments like Xeljanz and Eucrisa discounted up to 80%. The Most-Favored-Nation drug pricing policy creates additional pressure on domestic pricing. CEO Bourla described TrumpRx as "a win all across the board" — a characterization that sounds promotional but contains real logic: by agreeing to voluntary discounts that protect PFE from tariff exposure, the company trades pricing on some products for political protection on manufacturing and import costs. The net financial impact is negative in the short term — 2026 guidance explicitly incorporates the TrumpRx effect — but the alternative (unpredictable tariff exposure on a global supply chain) was arguably worse. The FDA's draft guidance easing biosimilar development requirements is a longer-term headwind that creates competition pressure across PFE's branded portfolio, potentially saving biosimilar developers $20 million in development costs and accelerating approval timelines by years. China holds the largest biosimilar pipeline globally and is actively penetrating FDA and EMA approval channels. This is a structural pressure, not a quarterly event.

The Dividend: 6.38% Yield With a Payout Ratio Above 100% — A Cut Is More Likely Than Not

PFE currently pays a dividend yielding 6.38% — approximately $9.8 billion annually. The FY2025 FCF was $9.08 billion, meaning the dividend payout ratio exceeds 100% of free cash flow. Full-year FCF guidance for 2026 implies further pressure as the LOE cycle begins. A dividend that exceeds 100% of FCF while simultaneously carrying substantial acquisition debt — primarily from the $43 billion Seagen purchase — is mathematically unsustainable over multiple years. A dividend cut at PFE would likely trigger a negative market reaction initially, as income-focused investors who hold the stock specifically for the 6.38% yield would sell. The rational response from management would be to cut the dividend to approximately $0.85-$0.90 per share annually — reducing yield to roughly 3-3.5% but preserving $4-5 billion of additional annual cash flow for debt reduction and pipeline investment. Paradoxically, a dividend cut that improves the balance sheet and accelerates debt paydown could be a long-term bullish catalyst even if it triggers short-term selling. The ViiV stake sale is already an example of the portfolio optimization strategy management is pursuing — and willingness to execute difficult balance sheet decisions is a positive management signal. However, Bourla explicitly stated the intention to "maintain and over the long term, grow" the dividend on the Q4 earnings call. That commitment creates near-term dividend cut risk if FCF deteriorates further than modeled.

DCF Valuation: Intrinsic Value of $28.90 Using Conservative Assumptions — $35 on Re-Rating

The DCF analysis using PFE's 2025 FCFF of approximately $11.35 billion, adjusted to $10 billion for 2026 as a base — an 11.9% decline — held flat through 2028 before growing at a 4% CAGR from 2029-2035 as the obesity and oncology pipeline matures, with a 2.5% terminal growth rate and WACC of 7.25%, produces an intrinsic value of $28.90 per share against the current $27.27. That $28.90 is derived using conservative FCF assumptions that the company's actual pipeline performance is likely to outpace. The more significant valuation catalyst is a P/E re-rating: at the current forward EPS of approximately $2.90 at the midpoint of guidance, a re-rating to just 12x forward earnings — still half the sector median — would produce a stock price of $34-$35. The $35 price target requires no heroic assumptions about obesity drug success or atirmociclib Phase 3 victory. It requires only that the market begins to assign Pfizer a P/E multiple roughly consistent with a pharmaceutical company in a transition cycle — not one that has permanently failed. The Tutanota mini-tender offer at $32 per share — while structured with a condition requiring the stock to close above $32 by April 13 — provides an independent datapoint that value investors are identifying $32 as a reasonable near-term acquisition price.

The Verdict: PFE Is a Buy at $27.27 — The Turnaround Is Not Priced In

Pfizer (PFE) is a buy at current levels. The 8.35x forward P/E, 6.38% dividend yield, and $28.90 DCF intrinsic value against $27.27 current price represent a compelling value setup for any portfolio with a 12-24 month time horizon. The oncology pipeline has delivered three major clinical wins in the past 60 days — BRAFTOVI approval, atirmociclib Phase 2 success, and Talzenna/Xtandi prostate trial primary endpoint. Lorbrena is growing at 47% year-over-year with five-year survival data that makes it the definitive standard of care in its indication. The obesity candidate PF'3944 has a once-monthly dosing advantage and efficacy projections approaching the tirzepatide benchmark. The LOE risk is real but is being overstated at current valuations. The dividend cut risk is the primary near-term negative catalyst to manage — size positions accordingly. A full position at current levels should use the $24-$25 range as the technical stop, which aligns with prior support and the Elliott Wave base. Price target of $35 within 18 months requires only a sector-median re-rating of a business that is executing better than its valuation implies.

That's TradingNEWS